A Review of Adverse Events From the Use of Diphtheria Antitoxin (DAT) in the United States, 2004-2019

Clin Infect Dis. 2022 Jun 10;74(11):2082-2083. doi: 10.1093/cid/ciab899.

Authors

Valerie D Bampoe¹, Haley C Boswell², Yon C Yu², Anna M Acosta¹

Affiliations

¹ Meningitis and Vaccine-Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USAand.
² Emergency Preparedness and Response Branch, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

No abstract available

Publication types

Review
Letter
Comment

MeSH terms

Diphtheria Antitoxin* / adverse effects
Diphtheria*
Humans
Neutralization Tests
United States / epidemiology

Substances

Diphtheria Antitoxin

Grants and funding

CC999999/ImCDC/Intramural CDC HHS/United States